Submodule
Platelet Adhesion, Activation, and Aggregation
Arterial thrombosis begins with platelet capture at vessel injury and progresses through agonist amplification, integrin activation, aggregation, and cooperation with thrombin and fibrin.
- vWF and GPIb adhesion
- ADP, thromboxane, and thrombin
- Granule secretion and cyclic AMP
- GPIIb/IIIa and fibrinogen
Anchor platelets at injured endothelium
Amplify shape change and secretion
Sustain activation and lower cyclic AMP
Bridge activated platelets
Capture platelets at the injury
Endothelial disruption exposes collagen and other thrombogenic material. Von Willebrand factor supports platelet capture through GPIb, especially under high shear. Adhesion stabilizes contact long enough for activation signals to intensify.
Amplify activation
Collagen, thrombin, ADP, and thromboxane A2 activate overlapping signaling pathways. Platelets change shape, release granule contents, recruit nearby platelets, and lower inhibitory cyclic AMP through P2Y12 signaling. Blocking one pathway reduces amplification but does not erase every activation route.
Build aggregation
Activation changes GPIIb/IIIa into a high-affinity state. Fibrinogen bridges adjacent platelets through this receptor, producing aggregation. Thrombin and fibrin from coagulation reinforce the developing platelet-rich arterial clot.
Match target to clinical intent
Aspirin blocks thromboxane production, P2Y12 inhibitors limit ADP-mediated amplification, and GPIIb/IIIa inhibitors block the final aggregation receptor. More targets can provide more ischemic protection but also increase bleeding, so indication and duration must be explicit.
Quick check
Submodule
Aspirin and Thromboxane Signaling
A short-lived drug produces prolonged platelet inhibition by irreversibly acetylating COX-1, while formulation, dose, allergy phenotype, GI protection, and nonprescription exposure shape safe use.
- Irreversible COX-1 acetylation
- Loading and maintenance
- GI bleeding mitigation
- Hypersensitivity phenotypes
Match formulation to urgency
Block arachidonic acid conversion
Reduce activation and vasoconstriction
Effect persists beyond plasma exposure
Suppress thromboxane for the platelet lifespan
Aspirin irreversibly acetylates platelet COX-1 and reduces thromboxane A2 synthesis. Because platelets cannot synthesize new COX-1, functional recovery depends largely on production of new platelets rather than on elimination of aspirin from plasma.
Load for speed, maintain for durability
A rapidly absorbed loading formulation is used when immediate platelet inhibition is needed. Maintenance dosing follows the indication and combination regimen. Enteric coating may delay absorption and should not be treated as equivalent during an acute loading need.
Protect the gastrointestinal tract
Assess prior ulcer or GI bleeding, anemia, age, anticoagulation, steroids, NSAIDs, alcohol, and kidney disease. Use gastroprotection when risk warrants it and remove avoidable NSAID or duplicate aspirin exposure without casually stopping necessary secondary-prevention therapy.
Name the reaction precisely
Respiratory reactions associated with asthma and nasal polyps, urticaria or angioedema, anaphylaxis, dyspepsia, and nonspecific intolerance require different responses. A precise history can support avoidance, supervised evaluation, desensitization, or safe continuation.
Quick check
Submodule
Oral P2Y12 Inhibitors
Clopidogrel, prasugrel, and ticagrelor share a receptor target but differ in metabolic activation, reversibility, consistency, administration, contraindications, interactions, and offset.
- Clopidogrel and CYP2C19
- Prasugrel and bleeding selection
- Ticagrelor kinetics and adverse effects
- Loading, maintenance, and adherence
CYP2C19 variability matters
Avoid after stroke or TIA
Twice daily with dyspnea risk
Balance ischemia, bleeding, access, and adherence
Activate clopidogrel through CYP2C19
Clopidogrel is a thienopyridine prodrug. Active metabolite formation depends substantially on CYP2C19, and patients with two loss-of-function alleles can have diminished platelet inhibition and higher cardiovascular event risk in ACS or PCI. Loading accelerates onset, while omeprazole and esomeprazole can reduce activation.
Use prasugrel only after contraindication review
Prasugrel is a prodrug that usually produces faster and more consistent irreversible P2Y12 inhibition than clopidogrel. Do not use it after prior stroke or TIA. Age 75 years or older and body weight below 60 kg increase bleeding concern and affect selection or maintenance dosing.
Use ticagrelor as a direct reversible inhibitor
Ticagrelor does not require activation to produce its parent antiplatelet effect and is dosed twice daily. Dyspnea, ventricular pauses, bleeding, adherence, and CYP3A interactions require review. Its current label pairs therapy with 75 to 100 mg of daily aspirin maintenance.
Plan transitions and procedures
A loading dose, maintenance schedule, and any switch must be written explicitly. Recovery differs by agent and patient. Before a procedure, coordinate ischemic risk, stent timing, procedure bleeding risk, last dose, and restart rather than applying one universal hold rule.
Quick check
Submodule
Intravenous P2Y12 and GPIIb/IIIa Agents
Cangrelor supplies rapid reversible P2Y12 inhibition during PCI, while eptifibatide and tirofiban produce potent final-pathway blockade for selected procedural needs.
- Cangrelor onset and offset
- Oral transition timing
- Eptifibatide and tirofiban
- Renal dosing and thrombocytopenia
Useful when oral therapy is not established
Prevent a gap or receptor competition
Renal dose and platelet surveillance
Renal adjustment and bleeding control
Use cangrelor for immediate reversible P2Y12 inhibition
Cangrelor is given as an intravenous bolus and infusion before PCI. It acts within minutes and has a half-life measured in minutes, so platelet function recovers rapidly after discontinuation. This is useful when oral inhibition is absent, delayed, or unreliable.
Time the oral transition
Ticagrelor may be given during the cangrelor infusion or immediately after it stops. Prasugrel and clopidogrel should be administered immediately after discontinuation because giving their active metabolites while cangrelor occupies the receptor can blunt the initial effect.
Reserve GPIIb/IIIa inhibitors for selected use
Eptifibatide and tirofiban block the final common aggregation receptor. Contemporary use is generally selective, such as procedural thrombotic complications or substantial thrombus burden, because routine exposure can add bleeding and thrombocytopenia.
Adjust and monitor
Use current weight and product-specific creatinine clearance thresholds to adjust infusion dosing. Obtain baseline hemoglobin, platelets, creatinine, and coagulation data when appropriate. Repeat platelets early because acute profound thrombocytopenia can occur.
Quick check
Submodule
Response Variability, Interactions, and Testing
Apparent antiplatelet failure can arise from nonadherence, access, inadequate loading, poor absorption, genetic activation differences, drug interactions, high platelet turnover, or a nonplatelet mechanism.
- Adherence and absorption
- CYP2C19 and CYP3A
- Genetic and platelet-function testing
- Switching and de-escalation
Confirm load, maintenance, and access
CYP2C19 and CYP3A can matter
Use only when a result can change care
Avoid blind dose escalation
Verify exposure before declaring failure
Confirm the loading dose, maintenance schedule, refill access, swallowing or vomiting, adherence, interruptions, and product interactions. Recurrent ischemia may also reflect stent mechanics, disease progression, or a noncoronary process rather than inadequate platelet inhibition.
Map the metabolic pathway
Clopidogrel requires CYP2C19 activation. Ticagrelor is affected by strong CYP3A inhibitors and inducers. Prasugrel has more efficient activation but remains limited by bleeding and contraindications. The relevant interaction pathway depends on the exact agent.
Test only when actionable
CYP2C19 genotype or platelet-function testing can support selected high-stakes decisions, especially when thrombosis risk is substantial and alternatives exist. Routine testing without a plan for each result adds complexity without ensuring better care.
Switch with an explicit objective
Escalation may improve platelet inhibition, while de-escalation may reduce bleeding or improve access and adherence. Define the reason, timing, need for reloading, interaction risks, and follow-up rather than treating P2Y12 inhibitors as interchangeable tablets.
Quick check
Submodule
Bleeding, Procedures, and Counseling
Safety requires rapid bleeding assessment, source control, product-aware offset, coordinated interruption, timely resumption, and patient instructions that prevent both hemorrhage and thrombosis.
- Bleeding severity and source control
- Reversal limitations
- Periprocedural interruption
- Adherence and warning counseling
Check hemodynamics, hemoglobin, and platelets
Stop active bleeding and restore perfusion
Account for agent-specific offset
Resume when hemostasis permits
Stabilize and control major bleeding
Assess airway, circulation, hemodynamics, bleeding site, hemoglobin, platelets, kidney and liver function, and every antithrombotic exposure. Stop active exposure when appropriate, obtain source control, provide supportive care, and involve procedural and specialty teams early.
Understand reversal limits
There is no single universal antidote strategy for every antiplatelet drug. Platelet transfusion and other supportive measures depend on timing, circulating drug, mechanism, severity, and source control. A laboratory value or transfusion does not replace clinical hemostasis.
Coordinate procedures
Elective procedure planning balances procedure bleeding risk against the indication and timing of antiplatelet therapy. Recent ACS or coronary stenting can make interruption dangerous. Agent-specific recovery, urgency, and the ability to delay the procedure shape the plan.
Counsel for safe persistence
Teach the exact schedule, missed-dose instructions, refill planning, avoidance of unreviewed NSAIDs and duplicate aspirin, expected bruising, urgent bleeding or neurologic symptoms, and the need to call before dental or surgical interruption. Use teach-back.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 104 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.
- AHA and ACC. 2025 Acute Coronary Syndromes Guideline
- DailyMed. Clopidogrel Prescribing Information
- DailyMed. Prasugrel Prescribing Information
- DailyMed. Brilinta Prescribing Information
- DailyMed. Kengreal Prescribing Information
- DailyMed. Eptifibatide Prescribing Information
- DailyMed. Tirofiban Prescribing Information